CEL-SCI CORPORATION Increase (Decrease) in Notes Payable, Current
CEL-SCI CORPORATION (CVM) reported Increase (Decrease) in Notes Payable, Current of $24.84 thousand for the 3-month period ending 2015-12-31, per its 10-Q filed 2016-02-09.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInNotesPayableCurrent · last filed 2016-02-09
- CEL-SCI CORPORATION increase (decrease) in notes payable, current for the quarter ending 2015-12-31 was $24.84K.
| Period end | Increase (Decrease) in Notes Payable, Current 3 month |
|---|---|
| 2015-12-31 | $24.84K 10-Q · filed 2016-02-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Quince Therapeutics, Inc. (QNCX) | United States | $0.031B | |
| aTYR PHARMA INC (ATYR) | United States | $0.033B | -0.98 |
| Estrella Immunopharma, Inc. (ESLA) | United States | $0.020B | |
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |
| Scilex Holding Co (SCLX) | United States | $0.042B | -0.14 |
| Metagenomi Therapeutics, Inc. (MGX) | United States | $0.044B | -0.48 |
| BioCardia, Inc. (BCDA) | United States | $0.016B | |
| DYADIC INTERNATIONAL INC (DYAI) | United States | $0.016B | |
| Passage BIO, Inc. (PASG) | United States | $0.015B | -0.43 |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |